BOCA RATON, FL--(Marketwire - November 17, 2008) - Vicor Technologies, Inc. (OTCBB: VCRT) President and CEO David H. Fater today issued the following letter to shareholders discussing Vicor's achieving various milestones and progress towards commercializing its PD2i technology. Vicor Technologies is a biotechnology company that developed the PD2i, a patented, proprietary algorithm now awaiting FDA 510(k) clearance for its first product, the PD2i Analyzer that measures heart rate variability, and is in clinical trials for 510(k) clearance for use of the PD2i algorithm in a) risk stratifying combat and civilian trauma victims (PD2i VS) and b) identifying patients at risk of suffering Sudden Cardiac Death (PD2i CA).
